(SeaPRwire) –   AI-fueled growth sees a sharp surge as Haier Biomedical advances from broad product coverage to premium brand leadership, developing a global platform for life science tools and intelligent productivity solutions

QINGDAO, China, April 30, 2026 — Haier Biomedical (688139.SH), a leading global provider of life science and medical solutions, has officially released its 2025 annual report, posting full-year revenue of 2.33 billion yuan (USD 340.77 million). Overseas revenue climbed 17.9% year-on-year to 840 million yuan (USD 122.85 million, making up 36% of total revenue — an all-time high. Even amid a complicated global trade landscape, Haier Biomedical delivered double-digit growth across all its international business segments.

Following a decade of global expansion, Haier Biomedical has transitioned from a “product export” model to full “brand globalization”. In 2025, overseas revenue recorded robust compound growth, with double-digit gains across Europe, Asia-Pacific, the Americas and Africa — including a 26.0% rise in the Asia-Pacific region and 16.0% growth in Europe.

For the first time, the company revealed its future strategic blueprint centered on “leapfrog growth”, powered by three core pathways: market leap, industry leap, and model leap. Its vision is to build a world-leading integrated platform for life science tools and intelligent productivity solutions.

Haier Biomedical continued to refine its revenue structure in 2025, with emerging market sectors and overseas operations emerging as its core growth engines. New business segments including smart medication management, blood technology, laboratory solutions and more contributed 48.5% of total revenue, representing an 8.8% year-on-year increase.

Its ultra-low and low-temperature biomedical freezers held the top market share position in six countries including Italy, while the firm also outperformed all domestic peers in export volume of smart medication dispensing solutions.

Revenue from AI-enabled applications made up 15% of total revenue, a 2.5 percentage point rise from 2024. The company has built a multi-tier AI infrastructure of “large models, AI agents, and AI terminals”, developing 17 proprietary agents integrated into 13 automated solutions. AI-powered automated pharmacies lifted direct dispensing rates to 80% — 1.1 times the industry average. Its fully automated cell workstation won the Ministry of Industry and Information Technology’s top award for disruptive technology, and its fully enclosed automated cell expansion system has entered clinical trials to support bioartificial liver treatments.

In addition, Haier Biomedical’s plasma separation system became the first Chinese-developed solution to obtain EU MDR certification. Its “Ultra Series” ultra-low temperature biomedical freezers have also delivered outstanding energy efficiency performance: all 8 top-ranked products in the ENERGY STAR program are from Haier Biomedical.

In 2025, the company’s R&D investment reached 320 million yuan (USD 46.82 million), with new invention patents rising 50% year-on-year to 1,620. Its on-time product launch rate improved by 11%, and 11 of its solutions achieved industry-first status. Haier Biomedical also became the first Chinese firm to master stable 100,000-rpm ultra-high-speed centrifugation technology, a breakthrough on a key technical bottleneck that further solidifies its core market competitiveness.

To date, Haier Biomedical holds more than 400 international product certifications and has formed partnerships with nearly 80 global organizations including the WHO and UNICEF. Its distribution network covers more than 800 partners across over 160 countries and regions. Committed to a “one country, one strategy” approach, Haier Biomedical has set up subsidiaries in four countries and localized operations in 18 more, combining fast delivery with on-the-ground local service to build deep, long-term global customer relationships.

After reshaping its growth trajectory in 2025, Haier Biomedical also unveiled its three-year “543” strategic targets in the annual report:

• Boost global market penetration through localized operations, with overseas revenue accounting for more than 50% of total revenue;
• Accelerate strategic industry expansion via platform-enabled external growth, with acquired businesses contributing no less than 40% of future revenue;
• Build future industry leadership through AI-powered innovation, with AI-related revenue making up over 30% of total revenue.

Moving forward, Haier Biomedical will leverage localized development, AI-driven innovation, and mergers and acquisitions as core catalysts to deliver comprehensive improvements in revenue structure, profit quality, and valuation fundamentals, advancing its goal of building a world-leading integrated life science tools and intelligent productivity platform.

To learn more, please visit https://www.haiermedical.com/.